TickerTalks
Browse all tickers →
TickerTalks›$CUE
CUCUE

Cue Biopharma, Inc.

$CUE·$71M·Biotechnology·Healthcare
$31.57-3.9%YTD+254.0%1Y+54.7%
Price updated 8m ago·X counts updated 23d ago
CUCUE
$CUECue Biopharma, Inc.
$31.57-3.90%37 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CUE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

37X posts · last 7 days
No mention history yet
Bearish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-03

Cue Biopharma is 'all-or-nothing' on a Phase 2 CSU/CUE-221 readout by September-end. A tracked predictions list explicitly calls CUE a miss, and a new SA article argues CUE-221 might not beat Omalizumab in CSU. Bulls hope for food-allergy separation as a fallback readthrough; skepticism dominates the sample.

Read what X is saying about $CUE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CUE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-09-24

The move is getting stronger, with heavier trading behind it.

Cue Biopharma's CUE-221 Phase 2 delivered positive top-line in chronic spontaneous urticaria — micro-cap up 242% year-to-date.

Cue Biopharma is a clinical-stage biotech developing selective T-cell modulators — CUE-221 for chronic spontaneous urticaria (CSU) is the lead asset with the specific dual-MOA angle. Micro-cap ($71M) up 242% year-to-date on the September readout.

  • The Phase 2 CUE-221 CSU data is the specific catalyst: positive top-line results with novel dual mechanism of action. That's a legitimate first-in-class biological read that opens both the CSU market and potentially food-allergy applications.
  • The bear voice on X is honest: bearish predictions on the September readout got beaten, and the counter-thesis (CUE-221 might not beat Omalizumab) is a real competitive concern for the CSU commercial launch.
  • Financials are what they are for a micro-cap post-catalyst: 100% gross margin on the tiny reported revenue with a fresh S-3 registration ready. The equity is priced on continued clinical execution plus commercial-partnership optionality.

November 11 earnings — CUE-221 next-step commentary, food-allergy readthrough data, and any specific commercial-partner disclosure is what extends the run; a specific safety issue or a competitor CSU Phase 3 win is the first real crack.

Differs from X sentimentThe X sample was bearish going into the September readout — 'all-or-nothing on a Phase 2 CSU/CUE-221 readout' with a tracked-predictions-list explicitly calling CUE a miss. The positive readout beat that skepticism, and the SA article arguing CUE-221 might not beat Omalizumab is a legitimate competitive-launch concern worth naming.

What to watch: November 11 earnings — CUE-221 next-step commentary, food-allergy readthrough data, commercial-partner disclosure; strong follow-through data or partnership announcement extends the run, a safety issue or competitor CSU Phase 3 win is the first crack.

On the calendar: 2026-11-11 — Q3 earnings

Read the AI verdict on $CUE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing fusion protein immunotherapies (CUE-101) to activate T cells against HPV-driven cancers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CUE.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

What this means for $CUE

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-78.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-59.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-35.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-98.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 14, 2026$-24.14$-1.69-1328.4%
Q1 2026May 14, 2026$-1.08$-3.30+67.3%
Q4 2025Mar 16, 2026$0.30$-2.70+111.1%
Q3 2025Nov 12, 2025$-2.10$-2.80+25.0%
Next earningsWed, Nov 11·consensus EPS $-2.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$5.7M+1250.6%100%-94.3%$-1.08$-11.1M
Q4 FY25$21.9M+1292.3%100%8.9%$0.44$-1.1M
Q3 FY25$2.1M-35.6%96.3%-351%$-2.21$-9.0M
Q2 FY25$3.0M+11.1%100%-292%$-2.66$-3.4M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.8M$12.8M – $12.8M-$6.64-$6.64 – -$6.641
FY27$1.0M$1.0M – $1.0M-$9.45-$9.45 – -$9.451
FY28$1.0M$1.0M – $1.0M-$15.30-$15.30 – -$15.301
FY29$1.0M$1.0M – $1.0M-$15.60-$15.60 – -$15.601

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.69%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+70.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β2.465-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 13Sumita RayChief Legal Compliance Officer8.8K sh$266KSellAug 13Meluzio Michael VincentVP, Prin. Accounting Officer5.6K sh$169KSellAug 13Shao-lee LinCEO18.3K sh$523KSellAug 12Shao-lee LinCEO40.0K sh$1.1MBuyJun 1Shao-lee LinCEO136.4K sh$500K
+ 21 other (18 awards · 3 exempts) in window

See when $CUE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 218-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
SC 13DActivist position (5%+)Aug 21SC 13D
AI summary

Dr. Shao-Lee Lin filed an initial Schedule 13D reporting beneficial ownership of 6.2% of Cue Biopharma (CUE), comprising 467,166 shares of common stock. Lin acquired all reported shares through employment compensation — RSU grants and stock options — upon her appointment as Chief Executive Officer on May 3, 2026. As the new CEO with a 6.2% stake, Lin's interests are meaningfully aligned with public shareholders. The Schedule 13D rather than 13G filing reflects her status as an officer with potential influence over the issuer, requiring the more detailed control-person disclosure form.

S-3Shelf registrationAug 12S-3
AI summary

Cue Biopharma (CUE) filed an S-3 shelf registration statement (not automatic effectiveness — a standard S-3 requiring SEC review), with CEO Shao-Lee Lin identified as agent, filed August 12, 2026. This shelf provides future flexibility to issue various securities but is not yet effective. Cue Biopharma is a Boston, MA clinical-stage immunology company developing precision biologics for oncology and autoimmune diseases.

8-KOfficer or director changeAug 38-K — Item 5.02: Officer or director change
AI summary

Cue Biopharma, Inc. (CUE) appointed Peter Ahlers as its new CFO, disclosing extensive life sciences finance experience: nearly two decades as CFO of Intarcia Therapeutics (>$1B in equity raises, >$150M in debt, >$600M in structured financings), consulting/CFO roles at RenovoRx, Arsenal Biosciences, Intensity Therapeutics through Danforth Advisors (2022–2026), and earlier positions at private life sciences companies. Ahlers brings significant public company finance and capital markets experience relevant to a biotech. This is a material leadership hire for a small-cap clinical-stage biotech.

3New insider — initial holdingsAug 33
AI summary

Cue Biopharma, Inc. (CUE) filed a Form 3 for a newly appointed officer (CFO based on role) as of August 3, 2026. The reporting person holds no securities of the issuer at the time of filing. Filed via attorney-in-fact Michael Meluzio. This is a routine initial insider ownership disclosure for a new officer with no current equity stake.

3New insider — initial holdingsJul 153
AI summary

Dominique Christian Borie filed an initial Form 3 on July 15, 2026, disclosing no beneficially owned securities of Cue Biopharma (CUE). Borie joined Cue Biopharma as Chief Medical Officer and Head of Research & Development, with an effective date of July 13, 2026. This filing initiates Borie's reporting obligations as an officer under Section 16(a) of the Securities Exchange Act.

8-KMaterial agreementJul 108-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

Cue Biopharma, Inc. closed a $50 million private placement on July 9, 2026, issuing 1,418,071 shares of common stock at $33.21/share plus pre-funded warrants for up to 87,500 shares at $33.209 each, to accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. The offering was unregistered (private placement) with securities subject to resale registration requirements. This is a dilutive $50M financing event for a clinical-stage biopharma — institutional participation from Cormorant and Columbia Threadneedle signals credible demand and provides runway for pipeline advancement.

S-3Shelf registrationJun 18S-3
AI summary

Cue Biopharma (CUE) filed a Form S-3 shelf registration statement on June 18, 2026, signed by CEO Shao-Lee Lin. The registration covers future securities offerings; the specific aggregate offering amount was not disclosed in the excerpt. This is a routine shelf filing enabling future capital raises.

+ 33 other (5 3s · 5 8-Ks · 4 EFFECTs · 3 CORRESPs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOAseekingalpha.com·4d agoCue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcriptseekingalpha.com·4d agoWhat's Going on With Cue Biopharma Stock on Monday?benzinga.com·4d agoCue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticariaglobenewswire.com·6d agoThis Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com·7d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $CUE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport